Issue

Vol. 66 No. 6: Issue 6

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Serum miR-885-5p can be used as a marker for efficacy prediction and prognosis of advanced liver cancer

https://doi.org/10.14715/cmb/2020.66.6.24
Kai Wang
Department of Hepatobiliary Surgery, Zhuji City People's Hospital, Zhuji 311800, P.R.China

Corresponding Author(s) : Kai Wang

kaiwang0207@163.com

Cellular and Molecular Biology, Vol. 66 No. 6: Issue 6

Abstract

This study set out to observe the value of miR-885-5p in the prognosis evaluation of liver cancer patients after transcatheter arterial chemoembolization. Sixty liver cancer patients treated in Zhuji City People's Hospital between January 2019 and September 2019 were enrolled. The patients were categorized into survival (SG) and death groups (DG) according to prognosis. Sixty-five healthy individuals were included as a control. The expression of miR-885-5p and miR-21were measured by the qRT-PCR and predictive value of diagnostic efficiency was determined by the ROC curve. Multivariate Cox regression analysis was performed to explore independent risk factors. Results showed that levels of miR-885-5p in the serum of liver cancer patients were obviously lower than that of the control group; however, levels of miR-21 in the serum of liver cancer patients were higher than that of healthy individuals. Patients with miR-885-5p low expression and miR-21 high expression had poor differentiation, stages III+IV, and their incidence of lymphatic invasion and distal metastasis was higher (P<0.05). AUC values of miR-885-5p and miR-21 single diagnosis were both > 0.8. The relative level of miR-885-5p in the serum of the SG was dramatically higher than that of the DG, and its relative level of miR-21 in serum was significantly decreased compared with DG. ROC curves in diagnosing the prognosis of liver cancer patients were drawn, AUC values of serum miR-885-5p and miR-21 in diagnosing their prognosis were both > 0.8. Cox regression analysis was carried out on independent factors affecting their prognosis. The results revealed that the TNM stage, lymphatic invasion, distal metastasis and miR-885-5p were independent prognostic factors affecting their 5-year survival. It was concluded that miR-885-5p exhibited the potential to be a serum biomarker to evaluate the efficacy of advanced liver cancer.

Keywords

miR-885-5p miR-21 Hepatocarcinogenesis The short-term prognosis.
Wang, K. (2020). Serum miR-885-5p can be used as a marker for efficacy prediction and prognosis of advanced liver cancer. Cellular and Molecular Biology, 66(6), 135–141. https://doi.org/10.14715/cmb/2020.66.6.24
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Feld JJ, Krassenburg LAP. What comes first: treatment of viral hepatitis or liver cancer? Dig Dis Sci 2019; 64(4): 1041-1049.
  2. Rao S, Mishra L. Targeting Transforming Growth Factor Beta Signaling in Liver Cancer. Hepatology 2019; 69(4): 1375.
  3. Kieckhaefer J, Maina F, Wells R, Wangensteen K. Liver cancer gene discovery using gene targeting, Sleeping Beauty, and CRISPR/Cas9. Seminars in liver disease. Thieme Med Publ 2019; 39(02): 261-274.
  4. Poynard T, Peta V, Deckmyn O, Munteanu M, Moussalli J, Ngo Y, Rudler M, Lebray P, Pais R, Bonyhay L, Charlotte F. LCR1 and LCR2, two multi"analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. Aliment Pharmacol Ther 2019; 49(3): 308-320.
  5. Seehawer M, Heinzmann F, D'artista L, Harbig J, Roux PF, Hoenicke L, Dang H, Klotz S, Robinson L, Doré G, Rozenblum N. Necroptosis microenvironment directs lineage commitment in liver cancer. Nature 2018; 562(7725): 69.
  6. Vannini I, Fanini F, Fabbri M. Emerging roles of microRNAs in cancer. Curr Opin Genet Dev 2018; 48: 128-133.
  7. Golabchi K, Soleimani"Jelodar R, Aghadoost N, Momeni F, Moridikia A, Nahand JS, Masoudifar A, Razmjoo H, Mirzaei H. MicroRNAs in retinoblastoma: Potential diagnostic and therapeutic biomarkers. J Cell Physiol 2018; 233(4): 3016-3023.
  8. Zare M, Bastami M, Solali S, Alivand MR. Aberrant miRNA promoter methylation and EMT"involving miRNAs in breast cancer metastasis: diagnosis and therapeutic implications. J Cell Physiol 2018; 233(5): 3729-3744.
  9. Schaapveld RQ, Verhaegh GW, Schalken JA, Van Puijenbroek AA, Gommans WM, Weijzen S. MiRNA molecule defined by its source and its diagnostic and therapeutic uses in diseases or conditions associated with EMT: U.S. Patent 9,944,932. 2018-4-17.
  10. Wang R, Sun Y, Yu W, Yan Y, Qiao M, Jiang R, Guan W, Wang L. Downregulation of miRNA-214 in cancer-associated fibroblasts contributes to migration and invasion of gastric cancer cells through targeting FGF9 and inducing EMT. J Exp Clin Cancer Res 2019; 38(1): 20.
  11. Su Q, Kumar V, Sud N, Mahato RI. MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Adv Drug Deliv Rev 2018; 129: 54-63.
  12. Minatel BC, Martinez VD, Ng KW, Sage AP, Tokar T, Marshall EA, Anderson C, Enfield KS, Stewart GL, Reis PP, Jurisica I. Large-scale discovery of previously undetected microRNAs specific to human liver. Hum genomics, 2018; 12(1): 16.
  13. Afonso MB, Rodrigues PM, Simí£o AL, Gaspar MM, Carvalho T, Borralho P, Bañales JM, Castro RE, Rodrigues CM. miRNA-21 ablation protects against liver injury and necroptosis in cholestasis. Cell Death Diff 2018; 25(5): 857.
  14. Mazzini GS, Khoraki J, Browning MG, Campos GM. Concurrent miR-21 suppression and FXR activation as a mechanism of improvement in nonalcoholic fatty liver disease. Cell Death Dis 2018; 9(3): 354.
  15. Santos AA, Afonso MB, Rodrigues PM, Castro RE, Rodrigues CM. Deregulation of small intestine permeability by miRNA-21 in liver disease. Free Radical Biol Med 2018; 120: S25.
  16. Huang Q, Zhang X, Bai F, Nie J, Wen S, Wei Y, Wei J, Huang R, He M, Lu Z, Lin X. Methyl helicterte ameliorates liver fibrosis by regulating miR-21-mediated ERK and TGF-β1/Smads pathways. Int Immunopharmacol 2019; 66: 41-51.
  17. Hama N, Totoki Y, Miura F, Tatsuno K, Saito-Adachi M, Nakamura H, Arai Y, Hosoda F, Urushidate T, Ohashi S, Mukai W. Epigenetic landscape influences the liver cancer genome architecture. Nat Commun 2018; 9(1): 1643.
  18. Vannini I, Fanini F, Fabbri M. Emerging roles of microRNAs in cancer. Curr Opin Genet Dev 2018; 48: 128-133.
  19. Liu Z, Sun J, Liu B, Zhao M, Xing E, Dang C. miRNA"‘222 promotes liver cancer cell proliferation, migration and invasion and inhibits apoptosis by targeting BBC3. Int J Mol Med 2018; 42(1): 141-148.
  20. Yan X, Liu X, Wang Z, Cheng Q, Ji G, Yang H, Wan L, Ge C, Zeng Q, Huang H, Xi J. MicroRNA"‘486"‘5p functions as a tumor suppressor of proliferation and cancer stem"‘like cell properties by targeting Sirt1 in liver cancer. Oncol Rep 2019; 41(3): 1938-1948.
  21. Chan C, Guo N, Duan X, Han W, Xue L, Bryan D, Wightman SC, Khodarev NN, Weichselbaum RR, Lin W. Systemic miRNA delivery by nontoxic nanoscale coordination polymers limits epithelial-to-mesenchymal transition and suppresses liver metastases of colorectal cancer. Biomater 2019; 210: 94-104.
  22. Sanchez"Mejias A, Kwon J, Chew XH, Siemens A, Sohn HS, Jing G, Zhang B, Yang H, Tay Y. A novel SOCS5/miR"18/miR"25 axis promotes tumorigenesis in liver cancer. Int J Cancer 2019; 144(2): 311-321.
  23. Xu F, Yan JJ, Gan Y, Chang Y, Wang HL, He XX, Zhao Q. miR-885-5p Negatively Regulates Warburg Effect by Silencing Hexokinase 2 in Liver Cancer. Mol Ther Nucleic Acids 2019; 18: 308-319.
  24. Liu H, Le Cheng DC, Zhang H. Suppression of miR-21 expression inhibits cell proliferation and migration of liver cancer cells by targeting phosphatase and tensin homolog (PTEN). Medical science monitor: Med Sci Monit 2018; 24: 3571.
  25. Koenig AB, Barajas JM, Guerrero MJ, Ghoshal K. A comprehensive analysis of argonaute-clip data identifies novel, conserved and species-specific targets of mir-21 in human liver and hepatocellular carcinoma. Int J Mol Sci 2018; 19(3): 851.
  26. Zavadil J, Juráćek J, Čechová B, Andrašina T, Slabí½ O, Goldberg N. Dynamic Changes in Circulating MicroRNA Levels in Liver Cancer Patients Undergoing Thermal Ablation and Transarterial Chemoembolization. Klinicka onkologie: casopis Ceske a Slovenske onkologicke spolecnosti, 2019; 32(Suppl1): 164-166.
  27. Wang XF, Zhang XL, Xu LP, Shi GG, Zheng HY, Sun BC. Expression of stem cell markers CD44 and Lgr5 in colorectal cancer and its relationship with lymph node and liver metastasis. Zhonghua Yi Xue Za Zhi, 2018; 98(36): 2899-2904.
  28. Akbari F, Arminian A, Kahrizi D, Fazeli A, Ghaheri M. Effect of nitrogen sources on gene expression of Stevia rebaudiana (Bertoni) under in vitro conditions. Cell Mol Biol, 64(2): 11-16.
  29. Ghaheri M, Adibrad E, Safavi SM, Kahrizi D, Soroush A, Muhammadi S, Ghorbani T, Sabzevari A, Ansarypour Z, Rahmanian E. Effects of life cycle and leaves location on gene expression and glycoside biosynthesis pathway in Stevia rebaudiana Bertoni. Cell Mol Biol, 64(2): 17-22.
  30. Kahrizi D, Ghaheri M, Yari Z, Yari K, Bahraminejad S. Investigation of different concentrations of MS media effects on gene expression and steviol glycosides accumulation in Stevia rebaudiana Bertoni. Cell Mol Biol, 64(2): 23-27.
  31. Hashempoor S, Ghaheri M, Kahrizi D, Kazemi N, Muhammadi S, Safavi SM, Ghorbani T, Rahmanian E, Heshmatpanaah M. Effects of different concentrations of mannitol on gene expression in Stevia rebaudiana Bertoni. Cell Mol Biol, 64(2): 28-31.
  32. Akbarabadi A, Ismaili A, Kahrizi D, Firouzabadi FN. Validation of expression stability of reference genes in response to herbicide stress in wild oat (Avena ludoviciana). Cell Mol Biol 2018; 64(4). 113-118.
  33. Ghorbani T, Kahrizi D, Saeidi M, Arji I. Effect of sucrose concentrations on Stevia rebaudiana Bertoni tissue culture and gene expression. Cell Mol Biol, 63(11): 32-36.
  34. Kahrizi D, Ghari SM, Ghaheri M, Fallah F, Ghorbani T, Beheshti AA, Kazemi E, Ansarypour Z. Effect of KH2PO4 on gene expression, morphological and biochemical characteristics of stevia rebaudiana Bertoni under in vitro conditions. Cell Mol Biol, 63(7): 107-111.
  35. Fallah F, Nokhasi F, Ghaheri M, Kahrizi D, Beheshti Ale AA, Ghorbani T, Kazemi E, Ansarypour Z. Effect of salinity on gene expression, morphological and biochemical characteristics of Stevia rebaudiana Bertoni under in vitro conditions. Cell Mol Biol 2017; 63(7): 102-106.
  36. Bordbar M, Darvishzadeh R, Pazhouhandeh M, Kahrizi D. An overview of genome editing methods based on endonucleases. Mod Genet J 2020; 15(2): 75-92.
  37. Ghaheri M, Kahrizi D, Bahrami G, Mohammadi-Motlagh HR. Study of gene expression and steviol glycosides accumulation in Stevia rebaudiana Bertoni under various mannitol concentrations. Mol Biol Rep 2019; 46(1): 7-16.
  38. Eruygur N, Ucar E, Akpulat HA, Shahsavari K, Safavi SM, Kahrizi D. In vitro antioxidant assessment, screening of enzyme inhibitory activities of methanol and water extracts and gene expression in Hypericum lydium. Mol Biol Rep 2019; 46(2): 2121-9.
  39. Esmaeili F, Ghaheri M, Kahrizi D, Mansouri M, Safavi SM, Ghorbani T, Muhammadi S, Rahmanian E, Vaziri S. Effects of various glutamine concentrations on gene expression and steviol glycosides accumulation in Stevia rebaudiana Bertoni. Cell Mol Biol, 64(2): 1-5.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 768 Download : 467